Julie R. Brahmer
Papers
1
Total Citations
299
H-Index
1
About
Dr. Julie R. Brahmer is a world-renowned thoracic oncologist whose pioneering research has fundamentally reshaped the treatment landscape for lung cancer. Her key contributions center on immunotherapy, particularly the development and clinical application of immune checkpoint inhibitors for non-small cell lung cancer (NSCLC). Dr. Brahmer’s landmark work includes the first-in-human studies of PD-1 blockade, establishing nivolumab as a transformative therapy for advanced NSCLC. Her highly cited 2018 study on neoadjuvant nivolumab in resectable disease (299 citations) demonstrated that immunotherapy before surgery is safe and induces major pathological responses, paving the way for a paradigm shift in early-stage lung cancer treatment. With a career spanning over two decades, her research has garnered tens of thousands of citations, reflecting her profound impact on clinical practice. Dr. Brahmer is also a leading voice in managing immune-related adverse events, having co-authored critical consensus guidelines. She serves as the Director of the Thoracic Oncology Program at the Johns Hopkins Kimmel Cancer Center and is a past President of the International Association for the Study of Lung Cancer (IASLC), cementing her legacy as a visionary in the fight against lung cancer.
Research Focus
Key Achievements
Top Papers
- 1